Key Points Rhythm Pharmaceuticals has commercially launched IMCIVREE in Japan for acquired hypothalamic obesity. The launch follows regulatory approval in August and inclusion on Japan’s…
October 14, 2026
September 10, 2026
Rhythm Highlights Setmelanotide Benefits in Pediatric Hypothalamic Obesity Studies
Key Points Rhythm Pharmaceuticals presented real-world and Phase 3 data on setmelanotide in children with acquired hypothalamic obesity at ESPE 2026. A French early-access analysis…
Key Points Rhythm Pharmaceuticals, Inc. reported preliminary Phase 2 data for RM-718, its investigational MC4R agonist. The early results support continued development of RM-718 in…
June 10, 2026
Lexaria Advances Next-Generation GLP-1 Research With Completion of Dosing in New Animal Study
Lexaria Bioscience Corp. (NASDAQ: LEXX) has completed dosing in its 2026 Animal Study #2 (GLP-1-A26-2), which is evaluating orally delivered formulations of two next-generation GLP-1…
Key Points Eligible Medicare patients living with obesity will gain access to Wegovy® (semaglutide) injection and pill for a $50 monthly copay. Alongside diet and…
The U.S. Food and Drug Administration has officially heightened its scrutiny of the booming metabolic health sector. This regulatory surge targets 30 distinct telehealth providers…
February 26, 2026
Eli Lilly Challenges the Needle with a $2B Oral Weight Loss Bet
Eli Lilly and Company (NYSE: LLY) recently reported breakthrough Phase 3 results for its investigational oral weight-loss and diabetes treatment, orforglipron. The company announced that…
February 25, 2026
Novo Nordisk: The Billion-Dollar Race for Obesity Pills
Novo Nordisk (NYSE: NVO) recently finalized a significant $2.1 billion agreement to expand its metabolic disease pipeline. This massive investment focuses on developing next-generation oral…
January 05, 2026
Novo Nordisk Begins U.S. Rollout of Wegovy Weight-Loss Pill
Novo Nordisk (NYSE: NVO) has begun rolling out an oral version of Wegovy® in the United States, expanding access to its blockbuster weight-loss therapy beyond…